{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T12:43:00Z","timestamp":1788525780591,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","issue":"36","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000008","name":"Health Canada","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000008","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.vaccine.2013.05.098","type":"journal-article","created":{"date-parts":[[2013,6,10]],"date-time":"2013-06-10T09:50:43Z","timestamp":1370857843000},"page":"3702-3711","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Quantitation of serogroups in multivalent polysaccharide-based meningococcal vaccines: Optimisation of hydrolysis conditions and chromatographic methods"],"prefix":"10.1016","volume":"31","author":[{"given":"Matthew C.","family":"Cook","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Bliu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy P.","family":"Kunkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2013.05.098_bib0005","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1016\/j.vaccine.2011.02.058","article-title":"The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease","volume":"29","author":"Harrison","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.05.098_bib0010","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4161\/hv.7.2.13717","article-title":"Meningococcal glycoconjugate vaccines","volume":"7","author":"Gasparini","year":"2011","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2013.05.098_bib0015","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2147\/IDR.S21545","article-title":"Meningococcal conjugate vaccines: optimizing global impact","volume":"4","author":"Terranella","year":"2011","journal-title":"Infect Drug Resist"},{"issue":"November","key":"10.1016\/j.vaccine.2013.05.098_bib0020","first-page":"521","article-title":"Meningococcal vaccines: WHO position paper","volume":"86","year":"2011","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2013.05.098_bib0025","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMra0906357","article-title":"Advances in the development of vaccines against Neisseria meningitidis","volume":"362","author":"Tan","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2013.05.098_bib0030","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1586\/erv.10.3","article-title":"The epidemiology of meningococcal disease and the impact of vaccines","volume":"9","author":"Khatami","year":"2010","journal-title":"Expert Rev Vaccines"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2013.05.098_bib0035","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1086\/648964","article-title":"Prevention of meningococcal disease: current use of polysaccharide and conjugate vaccines","volume":"50","author":"Poland","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2013.05.098_bib0040","doi-asserted-by":"crossref","first-page":"S285","DOI":"10.1097\/01.inf.0000147654.03890.b9","article-title":"Meningococcal vaccines","volume":"23","author":"Danzig","year":"2004","journal-title":"Pedatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2013.05.098_bib0045","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1586\/erv.09.18","article-title":"Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy","volume":"8","author":"Pace","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2013.05.098_bib0050","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1586\/erv.10.147","article-title":"Menveo: a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y","volume":"10","author":"Cooper","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2013.05.098_bib0055","first-page":"805","article-title":"Development of new vaccines against meningococcal disease","volume":"53","author":"Br\u00f6ker","year":"2003","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.vaccine.2013.05.098_bib0060","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1016\/j.vaccine.2009.07.036","article-title":"Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages","volume":"27","author":"Br\u00f6ker","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.05.098_bib0065","doi-asserted-by":"crossref","first-page":"343","DOI":"10.4155\/bio.09.181","article-title":"Bioanalysis of meningococcal vaccines","volume":"2","author":"Ravenscroft","year":"2010","journal-title":"Bioanalysis"},{"key":"10.1016\/j.vaccine.2013.05.098_bib0070","doi-asserted-by":"crossref","first-page":"B30","DOI":"10.1016\/j.vaccine.2009.05.003","article-title":"Quadrivalent meningococcal conjugate vaccines","volume":"27S2","author":"Pace","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.05.098_bib0075","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/adc.2006.111500","article-title":"Meningococcal A, C, W-135 polysaccharide\u2013protein conjugate vaccines","volume":"92","author":"Pace","year":"2007","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.vaccine.2013.05.098_bib0080","doi-asserted-by":"crossref","first-page":"881","DOI":"10.4161\/hv.6.11.12849","article-title":"Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo) or Menactra among healthy adolescents","volume":"6","author":"Gill","year":"2010","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2013.05.098_bib0085","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1097\/INF.0b013e31820e6e02","article-title":"Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile","volume":"30","author":"Memish","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2013.05.098_bib0090","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0929-6646(09)60371-5","article-title":"Safety and immunogenicity of a tetravalent polysaccharide vaccine against meningococcal disease","volume":"108","author":"Shao","year":"2009","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.vaccine.2013.05.098_bib0095","doi-asserted-by":"crossref","first-page":"846756","DOI":"10.4061\/2011\/846756","article-title":"Conjugate meningococcal vaccines development: GSK Biologicals experience","volume":"2011","author":"Miller","year":"2011","journal-title":"Adv Prev Med"},{"key":"10.1016\/j.vaccine.2013.05.098_bib0100","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1093\/infdis\/136.Supplement.S78","article-title":"Structures of the capsular polysaccharide of Neisseria meningitidis as determined by 13C-nuclear magnetic resonance spectroscopy","volume":"136","author":"Jennings","year":"1977","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2013.05.098_bib0105","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0731-7085(02)00462-4","article-title":"Use and validation of NMR assays for the identity and O-acetyl content of capsular polysaccharides from Neisseria meningitidis used in vaccine manufacture","volume":"30","author":"Jones","year":"2002","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.vaccine.2013.05.098_bib0110","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0003-2697(92)90349-C","article-title":"Carbohydrate composition analysis of bacterial polysaccharides: optimized acid hydrolysis conditions for HPAEC-PAD analysis","volume":"201","author":"Ip","year":"1992","journal-title":"Anal Biochem"},{"key":"10.1016\/j.vaccine.2013.05.098_bib0115","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/0264-410X(94)90219-4","article-title":"Quantification of polysaccharide in Haemophilus influenzae type b conjugate and polysaccharide vaccines by high-performance anion-exchange chromatography with pulsed amperometric detection","volume":"12","author":"Tsai","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.05.098_bib0120","first-page":"139","article-title":"Monitoring stability of meningococcal group C conjugate vaccines; correlation of physico-chemical methods and immunogenicity assays","volume":"103","author":"Ho","year":"2000","journal-title":"Dev Biol (Basel)"},{"key":"10.1016\/j.vaccine.2013.05.098_bib0125","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S0264-410X(00)00261-9","article-title":"Assessment of the stability and immunogenicity of meningococcal oligosaccharide C-CRM197 conjugate vaccines","volume":"19","author":"Ho","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.05.098_bib0130","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1016\/S0264-410X(02)00342-0","article-title":"Physico-chemical and immunological examination of the thermal stability of tetanus toxoid conjugate vaccines","volume":"20","author":"Ho","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.05.098_bib0135","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1016\/S0264-410X(00)00535-1","article-title":"Quantitative determination of C-polysaccharide in Streptococcus pneumoniae capsular polysaccharides by use of high-performance anion-exchange chromatography with pulsed amperometric detection","volume":"19","author":"Talaga","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.05.098_bib0140","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1016\/S0264-410X(02)00183-4","article-title":"Development of a high-performance anion-exchange chromatography with pulsed-amperometric detection based quantification assay for pneumococcal polysaccharides and conjugates","volume":"20","author":"Talaga","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.05.098_bib0145","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.biologicals.2007.01.003","article-title":"Evaluation of the saccharide content and stability of the first WHO International Standard for Haemophilus influenzae b capsular polysaccharide","volume":"35","author":"Mawas","year":"2007","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2013.05.098_bib0150","doi-asserted-by":"crossref","first-page":"6228","DOI":"10.1016\/j.vaccine.2010.07.005","article-title":"Immunogenicity and thermal stability of a combined vaccine against Haemophilus influenzae type b and Neisseria meningitidis serogroup C diseases","volume":"28","author":"Saydam","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.05.098_bib0155","first-page":"35","article-title":"Physicochemical characterisation of the oligosaccharide component of vaccines","volume":"103","author":"Ravenscroft","year":"2000","journal-title":"Dev Biol (Basel)"},{"key":"10.1016\/j.vaccine.2013.05.098_bib0160","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/S0264-410X(99)00535-6","article-title":"Quantitative determination of saccharide in Haemophilus influenzae type b glycoconjugate vaccines, alone and in combination with DPT, by use of high-performance anion-exchange chromatography with pulsed amperometric detection","volume":"18","author":"Bardotti","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.05.098_bib0165","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0264-410X(00)00427-8","article-title":"Development of a new method for the quantitative analysis of the extracellular polysaccharide of Neisseria meningitidis serogroup A by use of high-performance anion-exchange chromatography with pulsed-amperometric detection","volume":"19","author":"Ricci","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.05.098_bib0170","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/j.vaccine.2004.10.021","article-title":"Size determination of bacterial capsular oligosaccharides used to prepare conjugate vaccines against Neisseria meningitidis groups Y and W135","volume":"23","author":"Bardotti","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.05.098_bib0175","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.vaccine.2008.01.022","article-title":"Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases","volume":"26","author":"Bardotti","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.05.098_bib0180","unstructured":"Bardotti A, Proietti D, Ricci S. Analysis of saccharides vaccines without 577 interference. EP 1 725 872 B1; WO 2005\/090986 A2, 578 PCT\/IB2005\/000987."},{"key":"10.1016\/j.vaccine.2013.05.098_bib0185","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.biologicals.2012.03.003","article-title":"MenC IS Working Group. Evaluation of a candidate International Standard for Meningococcal Group C polysaccharide","volume":"40","author":"Vipond","year":"2012","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2013.05.098_bib0190","first-page":"259","article-title":"Quantification of free polysaccharide in meningococcal polysaccharide-diphtheria toxoid conjugate vaccines","volume":"103","author":"Lei","year":"2000","journal-title":"Dev Biol (Basel)"},{"key":"10.1016\/j.vaccine.2013.05.098_bib0195","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0731-7085(99)00183-1","article-title":"Quantitation of low level unconjugated polysaccharide in tetanus toxoid-conjugate vaccine by HPAEC\/PAD following rapid separation by deoxycholate\/HCl","volume":"21","author":"Lei","year":"2000","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.vaccine.2013.05.098_bib0200","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ab.2004.12.002","article-title":"Determination of meningococcal polysaccharides by capillary zone electrophoresis","volume":"338","author":"Lamb","year":"2005","journal-title":"Anal Biochem"},{"key":"10.1016\/j.vaccine.2013.05.098_bib0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.biologicals.2013.03.003","article-title":"Serogroup quantitation of multivalent polysaccharide and polysaccharide-conjugate meningococcal vaccines from China","author":"Cook","year":"2013","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2013.05.098_bib0210","unstructured":"European Pharmacopoeia. Meningococcal Polysaccharide Vaccine, 01\/2008:0250; Meningococcal Group C Conjugate Vaccine, 01\/2008:2112 corrected 6.0; Typhoid Polysaccharide Vaccine, 01\/2008:1160. Pneumococcal Polysaccharide Vaccine, 01\/2008:0966; Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed), 01\/20008:2150; Haemophilus Type b Conjugate Vaccine, 07\/2012:1219."},{"key":"10.1016\/j.vaccine.2013.05.098_bib0215","first-page":"39","article-title":"United States Pharmacopoeia \u2013 National Formulary. Proposal for General Chapter<1234>Vaccines for Human Use \u2013 Polysaccharide and Glycoconjugate Vaccines","year":"2013","journal-title":"Pharmacopeial Forum"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13007263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13007263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T17:11:07Z","timestamp":1645722667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X13007263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":43,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0264410X13007263"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.05.098","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantitation of serogroups in multivalent polysaccharide-based meningococcal vaccines: Optimisation of hydrolysis conditions and chromatographic methods","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.05.098","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown copyright \u00a9 2013 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}